C4 Therapeutics, Inc.

Name: C4 Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

CCCCNasdaqCIK 1662579HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$6.6m, Q2 FY2026

Operating income−$26.4m, Q2 FY2026

Net income−$23.6m, Q2 FY2026

C4 Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q1 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q1 FY20242024-06-30	Q1 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	11.1	3.3	3.0	12.0	15.4	5.2	7.2	6.5	11.2	11.0	6.2	6.6
Research and development	$m	28.3	30.4	22.5	23.8	31.8	32.5	27.1	26.2	26.0	25.0	24.6	24.5
Operating income	$m	(27.8)	(37.4)	(32.2)	(21.4)	(28.2)	(37.7)	(29.2)	(28.5)	(34.4)	(23.1)	(27.8)	(26.4)
Income tax	$m	1.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0
Net income	$m	(27.0)	(34.8)	(28.4)	(17.7)	(24.7)	(34.6)	(26.3)	(26.0)	(32.2)	(20.5)	(25.1)	(23.6)
Diluted EPS	$ per share	(0.55)	not reported	(0.41)	(0.26)	(0.35)	not reported	(0.37)	(0.37)	(0.44)	not reported	(0.20)	(0.18)
Basic EPS	$ per share	(0.55)	not reported	(0.41)	(0.26)	(0.35)	not reported	(0.37)	(0.37)	(0.44)	not reported	(0.20)	(0.18)

Balance sheet

Cash and equivalents$78.6m, Q2 FY2026

Long-term debt$0, FY2023

Shareholders' equity$247.3m, Q2 FY2026

C4 Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q1 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q1 FY20242024-06-30	Q1 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	61.0	127	89.7	73.1	59.6	55.5	51.3	78.2	58.8	74.6	61.3	78.6
Current assets	$m	224	271	280	276	273	258	233	225	207	258	245	263
Total assets	$m	333	376	398	381	376	350	320	297	265	359	329	359
Current liabilities	$m	30.3	42.8	55.0	54.2	43.3	45.2	40.8	44.5	35.9	33.0	27.2	48.2
Total liabilities	$m	117	130	140	134	133	134	124	122	111	102	94.6	112
Long-term debt	$m	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	216	246	258	247	243	216	195	174	154	257	234	247

Cash flow

Operating cash flow−$1.6m, Q2 FY2026

Capital expenditure$37.0k, Q2 FY2026

Share repurchases$0, Q2 FY2026

C4 Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(30.7)	(24.0)	(18.1)	(5.0)	(24.1)	(17.9)	(33.3)	(12.1)	(31.2)	(22.1)	(29.9)	(1.6)
Capital expenditure	$m	0.6	0.2	0.0	0.2	(0.0)	(0.0)	0.0	0.2	0.4	0.0	0.1	0.0
Share repurchases	$m	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.2	0.0

Diluted shares (weighted)130.70m, Q2 FY2026

C4 Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q1 FY20232023-06-30	Q1 FY20232023-09-30	Q1 FY20242024-03-31	Q1 FY20242024-06-30	Q1 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	48.9	49.0	49.1	49.2	68.4	68.8	69.6	70.8	71.0	72.6	126	131

Shares outstanding: 123.03m at Jul 31, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.